HGS is offering a genetic test for the pre-emptive screening of antibiotic-resistant, hypervirulent C difficile bacteria that differentiates more serious strains from other types of C difficile.
The new genetic test, called Easyscreen C difficile Complete, helps to distinguish the strains of C difficile that have evolved into the hypervirulent form that has caused severe illness and deaths overseas.
The test can also identify other types of hypervirulent C difficile such as the 078 strain.
Easyscreen C difficile Complete will be available for research use and is completed within four hours, requires minimal hands-on time and is compatible with most types of equipment commonly found in molecular testing laboratories.
The rapid and accurate nature of the Easyscreen C difficile Complete allows for it to be used as a screening test for patients in order to prevent future outbreaks.
The Easyscreen C difficile Complete uses HGS' proprietary 3base technology.
This test complements existing Human Genetic Signatures 3base assays for detection of Human Papilloma Virus (HPV), Methicillin Resistant Staphlycoccus aureus (MRSA), Vancomycin Resistant Enterococcus (VRE) and Hepatitis C (HCV).
